Ionising radiation induces the expression of a number of radiation-responsive genes and there is current interest in exploiting this to regulate the expression of exogenous therapeutic genes in gene therapy strategies for cancer. However, the radiation-responsive promoters used in these approaches are often associated with low and transient levels of therapeutic gene expression. We describe here a novel radiation-triggered molecular switching device based on promoter elements from the radiation-responsive Egr-1 gene and the cre-LoxP site-specific recombination system of the P1 bacteriophage. Using this system, a single, minimally
Introduction
Ionising radiation is currently used in the treatment of many human tumours and its potential for eliciting the expression of exogenous cancer therapeutic genes is of considerable current interest. In the majority of patients receiving radiotherapy, radiation is directed to the gross identifiable tumour, its presumed microscopic extension and frequently its known nodal drainage areas. This provides some degree of tumour localisation for controlling the expression of systemically delivered therapeutic genes. In the experimental models so far developed, therapeutic genes are usually prodrug activating ('suicide') or immunomodulating genes and their expression is controlled by locating them downstream of the promoter regions of genes that are up-regulated by ionising radiation. [1] [2] [3] [4] [5] [6] [7] For example, when the radiationresponsive Egr1 gene promoter was used to regulate expression of the human tumour necrosis factor alpha (TNF␣) gene in human tumour xenografts, increased growth inhibition was obtained compared with tumours treated with radiation alone. 5, 6, 8 Similarly, when the Egr1 promoter was used to control expression of the herpes toxic dose of radiation induced cre-mediated excision of a lox-P flanked stop cassette in a silenced expression vector and this resulted in amplified levels of CMV-promoter-driven expression of the exogenous tumour-sensitising gene, HSVtk. This strategy could be used in combination with targeted delivery and tumour-specific promoters to elicit the tumourtargeted and prolonged expression of a variety of tumoursensitising genes and provide an unprecedented level of control and tumour selectivity. Gene Therapy (2000) 7, 1121-1125.
simplex virus thymidine kinase (HSVtk) gene, enhanced tumour cell killing was seen when cells were grown in the presence of the anti-herpetic prodrug ganciclovir (GCV) following irradiation. 8, 9 The regions of the Egr1 gene promoter that control its radiation response have been identified and consist of 10-bp motifs known as CArG elements. 10 These elements are activated by a mechanism that is mediated by reactive oxygen species produced on exposure to ionising radiation. 11 We have recently demonstrated that a synthetic enhancer/promoter, containing four directly repeated CArG elements (E4), functions significantly better than the wild-type human Egr1 enhancer to up-regulate reporter gene expression after a single radiation dose as low as 2 Gy. 12 This synthetic enhancer/promoter has been exploited in developing the present strategy.
One of the problems associated with the use of ionising radiation to regulate gene expression is that the response is well established to be transient and increased gene expression is thus only maintained for a brief period after the radiation stimulus is withdrawn. 1, 2 To address this problem, we have devised a molecular 'switch' based on the Cre/loxP recombination system of bacteriophage P1. [13] [14] [15] [16] The novelty of this approach is that instead of controlling the expression of the tumour sensitising gene, the radiation responsive promoter controls the expression of Cre recombinase. This then activates a transcriptionally silenced tumour sensitising gene by loxP site mediated recombination. Since the CMV IE promoterenhancer provides efficient and sustained expression of downstream genes, 17, 18 expression should be both prolonged and at a substantially increased level.
Results
Operation of molecular switch in human tumour cells We first established that the molecular switch we proposed to use in the suicide gene strategy could operate in human tumour cells in vitro by means of transfection with two separate plasmids (Figure 1 ). One plasmid (pcre) contained the Cre recombinase protein coding region located downstream of the cytomegalovirus immediate-early (CMV IE) enhancer-promoter. The other plasmid (pSGFP) contained the green fluorescent protein (GFP) 19 reporter gene downstream of the CMV IE enhancer-promoter but separated from it by a transcriptional silencer ('stop cassette') which prevented GFP expression. The stop cassette was flanked by loxP recognition/cleavage sites, so that the expression of Cre recombinase encoded by the other plasmid would result in the removal of the stop cassette (producing p⌬SGFP in Figure 1 ) and hence permit GFP expression. Human MCF-7 breast adenocarcinoma cells were singly transfected with either plasmid or cotransfected with both, using the cationic lipid reagent, Lipofectamine. Subsequent GFP production was measured by fluorescent activated cell sorting (FACS) analysis. 19, 20 Only in cultures transfected with both plasmids were any highly fluorescent cells observed (4.3 ± 0.4% of the cell population) confirming that the molecular switch is able to operate in these tumour cells following transfection of individual plasmids.
Radiation-mediated activation of the molecular switch
To make the molecular switch radiation-responsive, the CMV enhancer in pcre was replaced with our synthetic radiation-responsive enhancer 12 to create pE4cre. A plasmid (pE4GFP) in which GFP production was directly controlled by the E4 enhancer-CMV IE promoter (hereafter, E4) was used as a comparative control. increase in the total number of highly fluorescent cells when compared with unirradiated controls, confirming that GFP gene expression could be directly controlled by E4. However, GFP production was substantially greater when the Cre/loxP switch system was employed. Thus, in cultures transfected with both pE4cre and pSGFP and irradiated, the total number of fluorescent cells increased by 8.2 ± 1.1-fold compared with their unirradiated controls. Moreover, the median intensity of fluorescence was 14.4 times higher than in the cells transfected only with pE4GFP and irradiated (data not shown). These results indicate that a very substantial amplification of the radiation signal (approximately 40-fold) can be achieved by means of the molecular switch. The system we describe thus exploits the benefits of a specific, targetable, though transient and relatively weak, triggering event to elicit very high level, and probably continuous, gene expression.
Radiation-mediated cell killing
To assess the feasibility of using the Cre/loxP switch system in cancer therapy, we adopted a suicide gene strategy in a standard in vitro tumour cell growth-inhibition assay. To do this, the GFP protein coding region in pSGFP was replaced by the HSVtk coding sequence 21 to create pStk. In addition, to avoid the potential problems of simultaneous plasmid transfections, a stable MCF-7 cell line that would express the cre gene upon irradiation (MCF-7/E4cre) was produced by transfection with pE4cre followed by G418 selection. The MCF-7/E4cre cell line was then transfected with pStk, irradiated and the inhibition of cell growth in the presence of GCV compared with that observed in the appropriate controls.
MCF-7/E4cre cells that were transfected with the pStk plasmid were considerably more sensitive to radiation-GCV therapy than the control MCF-7/E4cre cells ( Figure 2a , P Ͻ 0.001, two-way analysis of variance). Indeed, the molecular switch resulted in almost the same increase in sensitivity as that achieved by transfection of
Figure 2 Tumour cell growth in vitro in the presence of GCV, after increasing doses of radiation. (a) MCF-7/E4cre cells (᭺), MCF-7/E4cre cells transfected with pStk (᭹) and MCF-7 cells transfected with ptk (̄). (b) MCF-7 cells (ᮀ), MCF-7 cells transfected with pE4tk (). Error bars are shown in one direction only for clarity.
the plasmid in which tk expression was directly controlled by the CMV IE enhancer-promoter (Figure 2a , P Ͻ 0.001). This indicates that following irradiation the promoter region of the E4cre vector elicits sufficient cre gene expression to activate the target (pStk) plasmids and hence that the efficiency of the system appears not to be limited by the molecular switch itself. The switchmediated sensitisation to GCV resulted in an increased growth inhibition at 2 Gy of 27% when compared with the control MCF-7/E4cre cells (Figure 2a) . This was considerably greater than the 8% increase in sensitivity seen in irradiated MCF-7 cells that were transfected with the plasmid, pE4tk, in which HSVtk gene expression was under the direct control of E4 (Figure 2b , P = 0.014). The switch thus provides a further three-fold increase in cell growth inhibition in comparison with using the radiation-responsive promoter alone to drive HSVtk expression.
Discussion
Several previous studies have employed radiation in suicide gene strategies. Kim et al 22 found that radiation enhanced the sensitivity of a glioma cell line constitutively expressing the HSVtk gene to the prodrug, 5-(2-bromovinyl)-2′-deoxyuridine, presumably by synergy with the DNA damaging effects of radiation. Radiationresponsive promoter-mediated prodrug activation has been demonstrated in a number of in vitro systems including glioma 8, 23 and pancreatic 9 cell lines transfected with plasmids in which the wild-type Egr1 promoter directly controlled HSVtk production. Similarly, this promoter has been used to control the growth of tumour xenografts via expression of the TNF␣ gene. 6, 8 However, in most studies the results were achieved using a total dose of 20-50 Gy (sometimes given as multiple 5 Gy fractions). In the present study, substantial additional tumour cell growth inhibition was achieved by the switch system after a single exposure to doses as low as 1 Gy (Figure 2 ). Indeed this dose produced cell growth inhibition equivalent to that of 3 Gy without the switch, resulting in an exceptionally high radiation dose modifying factor of approximately 4. Whilst a suicide gene is likely to elicit the greatest killing effect in the cells that are induced to express it, we expect that more extensive and widespread prodrug-mediated cell killing would be achieved under in vivo conditions where local (connexinmediated) [24] [25] [26] or systemic (immune system-mediated) [27] [28] [29] bystander effects and cytotoxicity synergies 22 will occur. The possibility that the prodrug activating protein could be expressed as a fusion protein with a cellular transporter such as VP22 30 to exploit the sustained expression of the switched vector further, might also be considered.
A Cre/loxP switch system has been previously used to control reporter gene expression via either the CMV enhancer/promoter, 16, [31] [32] [33] murine ␣A-crystallin promoter 33 or hepatocarcinoma-associated ␣-fetoprotein promoter (AFP). 34 This latter scheme produced a 50-fold increase in expression compared with that obtained by using the AFP promoter directly to control reporter gene expression. This is comparable with the approximately 40-fold increase we observed using our E4/Cre system. However, the present report is the first to use a Cre/loxP switch system to achieve tumour cell killing and the first Gene Therapy to use clinically relevant (daily) single doses of radiation to drive the response.
In conclusion, we believe this type of molecular switch system has the potential to overcome problems of low and transient levels of therapeutic gene expression associated with some current radiation-mediated gene therapy schemes. Our strategy will be particularly beneficial in situations where specific, but relatively weak radiation-responsive promoters are employed to target gene expression to a tumour. Additional possibilities may be provided by the further confinement of the irradiated volume using conformal, interstitial or brachytherapy techniques and by the demonstration that the radiation responsive promoters can be activated by radioisotopes 9 which may be targetable to some tumour types. The promoter/switch combination, which can be engineered into a single vector, will provide specific, high-level and probably prolonged expression of one or more of the wide range of therapeutic genes, 35 including immunomodulators 36 and tumour-specific promoters 37 now available. It will enable targeted and effective gene therapy approaches to be exploited for the treatment of cancer, given the appropriate therapeutic DNA delivery systems and the other caveats of gene therapy.
38,39
Materials and methods
Vector construction
The Cre recombinase open reading frame (ORF) was subcloned as an XhoI/MluI fragment from pBS185 into pCIneo (plasmids from GibcoBRL, Paisley, UK). The spacer/transcription stop cassette was subcloned from pBS302 (Gibco BRL) as an EcoRI/SpeI fragment into the EcoRI/XbaI site of pCIneo. The GFP ORF was then subcloned as an AccI/NotI fragment from pEGFP-1 (Clontech, Basingstoke, UK). The HSVtk ORF was derived by PCR amplification from the original plasmid clone 21 using primers; 5′-GCTCTAGAGTCGACATGG CTTCGTACCCCGGC-3′ and 5′-CCATCGATCTCCTT-CCGTGTTTCAGTTAGC-3′. Amplification was performed for 10 cycles of 15 s at 94°C, 30 s at 50°C and 60 s at 72°C, with a further five cycles in which the elongation step was sequentially increased by 20 s each round. The Expand Hi-Fidelity PCR System (Boehringer Mannheim, Lewes, UK) was used to minimise the introduction of mutations into the product. The PCR product was then purified using a Nucleon PCR/Oligo Clean-Up kit, digested with XbaI/NotI and cloned into the corresponding sites in pCIneo (to create ptk) or pE4GFP (replacing the GFP ORF and producing pE4tk). The HSVtk ORF was sequenced on both strands using the ABI Prism Kit and 373A Sequencer (Applied Biosystems, Warrington, UK) to verify its sequence integrity. The stop cassette was cloned as before to create pStk. The E4 synthetic promoter was cloned as described previously. ) were treated with Lipofectamine (GibcoBRL) using a modification of the manufacturer's procedure. Five microgrammes of plasmid DNA (in 10 l ddH 2 O) was mixed with 90 l of serum-free medium (SFM) and incubated for 45 min at room temperature with a mixture of 15 l Lipofectamine (2 mg/ml) and 85 l SFM and the resultant complex mixture added to a monolayer of pre-confluent cells seeded in a six-well Multiwell tissue culture plate for 5 h, removed by aspiration and replaced with 1 ml prewarmed complete medium. For reporter assay, cell monolayers were trypsinised 72 h after transfection, washed three times with 1 ml of cold PBS by centrifugation and resuspension, and finally resuspended in 0.5 ml of PBS for FACS analysis.
FACS analyses
For each sample (1-10 × 10 5 cells) were analysed on a Becton Dickinson FACScan flow cytometer as described previously. 12 The transfection efficiency in each experiment was determined using a plasmid in which GFP production was controlled by the CMV IE enhancer/promoter (pGFP) and was found to be consistently 20% per plasmid.
Irradiation and expression analyses
Cell monolayers were irradiated at 37°C using a Cre-expressing cell line To establish a cell line that constitutively contained a radiation-inducible Cre recombinase, MCF-7 cells were transfected with the pE4cre plasmid and then subjected to G418 selection. Cell lines were cloned by serial dilution in G418 (0.5 mg/ml). The presence of the cre gene verified by PCR amplification using Cre1: 5′-ACGACCAAGTGA-CAGCAATGC-3′ and Cre2 5′-AACCAGCGTTTT CGTTCTGCC-3′. Genomic DNA was prepared using the IGI Genomic G2 DNA Extraction Kit (Immunogen, Norwood, MA, USA). Screening was carried out on purified DNA using the Reddy-Load PCR system (Advanced Biotechnologies, Silverdale, WA, USA) using the following amplification cycle; 30 cycles of 1 min at 94°C, 1.5 min at 55°C and 1.5 min at 72°C, with a final 5 min extension time at 72°C. The same technique was used to establish the MCF-7/E4tk cell line, screening being carried out using the tk primers detailed above. Cell lines were grown routinely in RPMI medium with 10% FCS supplemented with G418. The population doubling time of exponentially growing cells and the cell cycle distribution of confluent cell cultures of the MCF-7, MCF-7/E4cre and MCF-7/E4tk cell lines were similar.
Cell growth inhibition studies MCF-7 cells and cell lines were transfected with either pE4cre, pStk or ptk plasmids using the procedure described above. Twelve hours after transfection, monolayers were trypsinised and cells processed for radiationmediated growth inhibition as a measure of cytotoxicty, as described previously. 12 Cell growth was calculated in the presence and absence of 50 m GCV for all six cell lines in two independent experiments. The working concentration of GCV (50 m) had a negligible effect on the growth of untransfected cells. For each radiation dose point cell growth was assessed from 48 individual measurements per experiment. The mean plating efficiency (PE) for each cell line was calculated from an unirradiated cell population in the presence or absence of GCV from 48 individual measurements. The mean PE values were then used to calculate individual measures of growth for each irradiated cell population. A mean value of growth was then calculated from the 48 individual measurements from each experiment, then data from the two independent experiments combined.
